These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 25697774)

  • 1. Incidence and risk of hypertension with ramucirumab in cancer patients: a meta-analysis of published studies.
    Wang J; Wang Z; Zhao Y
    Clin Drug Investig; 2015 Apr; 35(4):221-8. PubMed ID: 25697774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and risk of hypertension associated with ramucirumab in cancer patients: A systematic review and meta-analysis.
    Qi WX; Fu S; Zhang Q; Guo XM
    J Cancer Res Ther; 2016; 12(2):775-81. PubMed ID: 27461650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab.
    Arnold D; Fuchs CS; Tabernero J; Ohtsu A; Zhu AX; Garon EB; Mackey JR; Paz-Ares L; Baron AD; Okusaka T; Yoshino T; Yoon HH; Das M; Ferry D; Zhang Y; Lin Y; Binder P; Sashegyi A; Chau I
    Ann Oncol; 2017 Dec; 28(12):2932-2942. PubMed ID: 28950290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis.
    Roviello G; Pacifico C; Corona P; Generali D
    Invest New Drugs; 2017 Aug; 35(4):518-523. PubMed ID: 28285368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis.
    Ranpura V; Pulipati B; Chu D; Zhu X; Wu S
    Am J Hypertens; 2010 May; 23(5):460-8. PubMed ID: 20186127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and relative risk of hemorrhagic events associated with ramucirumab in cancer patients: a systematic review and meta-analysis.
    Tian R; Yan H; Zhang F; Sun P; Zheng X; Zhu Y; Wang Q; He J
    Oncotarget; 2016 Oct; 7(40):66182-66191. PubMed ID: 27507055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis.
    Qi WX; Lin F; Sun YJ; Tang LN; He AN; Yao Y; Shen Z
    Cancer Chemother Pharmacol; 2013 Feb; 71(2):431-9. PubMed ID: 23178953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.
    Ranpura V; Hapani S; Chuang J; Wu S
    Acta Oncol; 2010 Apr; 49(3):287-97. PubMed ID: 20156114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.
    Fuchs CS; Tomasek J; Yong CJ; Dumitru F; Passalacqua R; Goswami C; Safran H; Dos Santos LV; Aprile G; Ferry DR; Melichar B; Tehfe M; Topuzov E; Zalcberg JR; Chau I; Campbell W; Sivanandan C; Pikiel J; Koshiji M; Hsu Y; Liepa AM; Gao L; Schwartz JD; Tabernero J;
    Lancet; 2014 Jan; 383(9911):31-39. PubMed ID: 24094768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of gastrointestinal perforation in cancer patients receiving ramucirumab: a meta-analysis of randomized controlled trials.
    Wang Z; Zhang J; Zhang L; Liu P; Xie Y; Zhou Q
    J Chemother; 2016 Aug; 28(4):328-34. PubMed ID: 26099278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of hematological toxicities in patients with solid tumors treated with ramucirumab: a meta-analysis.
    Abdel-Rahman O; ElHalawani H
    Future Oncol; 2015; 11(21):2949-61. PubMed ID: 26422782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.
    Nalluri SR; Chu D; Keresztes R; Zhu X; Wu S
    JAMA; 2008 Nov; 300(19):2277-85. PubMed ID: 19017914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of cardiovascular adverse events in patients with solid tumors treated with ramucirumab: A meta analysis and summary of other VEGF targeted agents.
    Abdel-Rahman O; ElHalawani H
    Crit Rev Oncol Hematol; 2016 Jun; 102():89-100. PubMed ID: 27129437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comment on: Incidence and Risk of Hypertension with Ramucirumab in Cancer Patients: A Meta-Analysis of Published Studies.
    Sashegyi A; Lin Y; Ferry D; Melemed A
    Clin Drug Investig; 2015 Jun; 35(6):405. PubMed ID: 25910606
    [No Abstract]   [Full Text] [Related]  

  • 15. Ramucirumab: A Review in Advanced Gastric Cancer.
    Greig SL; Keating GM
    BioDrugs; 2015 Oct; 29(5):341-51. PubMed ID: 26341713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials.
    Xiao B; Wang W; Zhang D
    Onco Targets Ther; 2018; 11():5059-5074. PubMed ID: 30174444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis.
    An MM; Zou Z; Shen H; Liu P; Chen ML; Cao YB; Jiang YY
    Eur J Clin Pharmacol; 2010 Aug; 66(8):813-21. PubMed ID: 20401474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.
    Funakoshi T; Latif A; Galsky MD
    Cancer Treat Rev; 2013 Nov; 39(7):818-30. PubMed ID: 23455076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study.
    Yardley DA; Reeves J; Dees EC; Osborne C; Paul D; Ademuyiwa F; Soliman H; Guthrie T; Andersen J; Krekow L; Choksi J; Daniel B; Danso M; Favret A; Oommen S; Brufsky A; Bromund JL; Lin Y; Ibrahim AB; Richards PD
    Clin Breast Cancer; 2016 Dec; 16(6):471-479.e1. PubMed ID: 27569274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
    Wilke H; Muro K; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Sugimoto N; Lipatov O; Kim TY; Cunningham D; Rougier P; Komatsu Y; Ajani J; Emig M; Carlesi R; Ferry D; Chandrawansa K; Schwartz JD; Ohtsu A;
    Lancet Oncol; 2014 Oct; 15(11):1224-35. PubMed ID: 25240821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.